Publications:
In preparation
Correlation of adenoviral titers with severity of adenoviral conjunctivitis and viral clearance over 21 days.
Submitted/Under Review
Diagnostic Accuracy of Adenoviral Conjunctivitis Using Signs, Symptoms and point-of-care-testing. Clinical and Experimental Optometry.
Published
Shorter ES, Whiteside MM, Harthan JS, Morettin CE, Perera CD, Johnson SD, Migneco MK, Huecker JB, Hartwick ATE, Than TP, Gordon MO. Diagnostic accuracy of clinical signs, symptoms and point-of-care testing for early adenoviral conjunctivitis. Clin Exp Optom. 2022 Sep;105(7):702-707. Epub 2021 Nov 9. PMID: 34751088; PMCID: PMC9081290.
Than T. Facts and Fiction about Adenoviral Conjunctivitis. Review of Optometry. November 15, 2022.
Johnson SD, Harthan JS, Than T, Migneco MK, Shorter E, Whiteside MM, Morettin CE, Olson CK, Rosemann CA, Margolis MS, Haertter LW, Huecker JB, Rodic-Polic B, Buller RS, Storch GA, Gordon MO, Hartwick ATE. Predictive Accuracy and Densitometric Analysis of Point-of-Care Immunoassay for Adenoviral Conjunctivitis. Transl Vis Sci Technol. 2021;10(9):30. PMID: 34431990. PMCID: PMC8399540. Supplement.
Than T, Morettin CE, Harthan JS, Hartwick ATE, Huecker JB, Johnson SD, Migneco MK, Shorter E, Whiteside M, Olson CK, Alferez CS, van Zyl T, Rodic-Polic B, Storch GA, Gordon MO. Efficacy of a Single Administration of 5% Povidone-Iodine in the Treatment of Adenoviral Conjunctivitis. Am J Ophthalmol. 2021;231:28-38. PMID: 34102153. Supplement.
Whiteside MM, Shorter ES, Margolis MS, Alvi F, Huecker JB, Than TP, Migneco MK, Harthan JS, Morettin CE, Hartwick ATE, Johnson SD, Perera CD, Gordon MO. Success of Masking 5% Povidone-Iodine Treatment: The Reducing Adenoviral Patient Infected Days Study. Optom Vis Sci. 2021;98(5):469-475. PMID: 33973917. PMCID: PMC8665724.
Shorter E, Whiteside M, Harthan J, Margolis MS, Hartwick AT, Johnson S, Migneco M, Morettin C, Olson CK, Huecker J, Than T, Gordon MO. Safety and tolerability of a one-time, in-office administration of 5% povidone-iodine in the treatment of adenoviral conjunctivitis: The Reducing Adenoviral Patient Infected Days (RAPID) study. Ocul Surf. 2019. PMID:31401340. PMCID: PMC6874762.
Letter to the Editor: Effect of Povidone Iodine 5% on the Cornea, Vision, and Subjective Comfort. Optom Vis Sci 2017;94(7):732-41.
Article was editor’s choice for 2014 and also top 5 most popular stories among readers.
Tammy T, Hartwick ATE, Shorter E, Johnson S, Lonsberry B, Gordon MO, Freddo T “How to Manage Adenoviral Conjunctivitis” Optometry Times, Feb. 2014.
Posters and Presentations:
2021
Morettin C, et al. Correlation of adenoviral load with severity of adenoviral conjunctivitis and viral clearance over 21 days. May 2021. Submitted to the Association for Research in Vision and Ophthalmology Annual Meeting. Virtual.
2020
Shorter E, et. al. Using signs and symptoms to improve diagnostic accuracy of adenoviral conjunctivitis for primary care providers. October 2020. Accepted at the American Academy of Optometry Annual Meeting, Nashville, TN.
Morettin C, et. al. Correlation of Signs and Symptoms with Viral Load in Patients with qPCR Confirmed Adenoviral Conjunctivitis over 21 Days. October 2020. Accepted at the American Academy of Optometry Annual Meeting, Nashville, TN.
Shorter E. et. al. Improving accuracy of adenoviral conjunctivitis diagnosis. May 2020. Accepted at the Association for Research in Vision and Ophthalmology Annual Meeting, Baltimore, MD. Poster board Number: 4900 – B0064.
2019
Shorter E, et. al. Economic Burden of Conjunctivitis: Reducing Adenoviral Patient Infected Days (RAPID) Study. October 2019. Accepted at the American Academy of Optometry, Baltimore, MD. #4900-B0064.
Harthan, J, et. al. Densitometric analysis of point-of-care adenoviral chromatographic immunoassays (AdenoPlusTM) in individuals with acute conjunctivitis. October 2019. Presented at the American Academy of Optometry, Orlando, FL. Board #102.
Whiteside, M, et. al. Assessment of Treatment Masking: The Reducing Adenoviral Patient Infected Days (RAPID) Study. October 2019. Presented at the American Academy of Optometry, Orlando, FL. Board #191.
Hartwick ATE, et. al. Reducing Adenoviral Patient-Infected Days (RAPID) Study: A Randomized Trial Assessing Efficacy of One Time, In-Office Application of 5% Povidone-Iodine in Treatment of Adenoviral Conjunctivitis. May 2019. Presented at the Association for Research in Vision and Ophthalmology Annual Meeting, Vancouver, BC. #6257-B0238.
Shorter E, et. al. The Reducing Adenoviral Patient-Infected Days (RAPID) Study: Safety and Tolerability of One-Time, In-Office Application of 5% Povidone-Iodine in the Treatment of Adenoviral Conjunctivitis. May 2019. Presented at the Association for Research in Vision and Ophthalmology Annual Meeting, Vancouver, BC. #3139517.
2018
Johnson S.D., et. al. Predictive Value of FDA-Approved Immunoassay for Adenoviral Conjunctivitis. November 2018. Presented at the American Academy of Optometry, San Antonio, Texas.
Shorter E, et. al. Reducing Adenoviral Patient Infected Days (RAPID): Tolerability of a Single In-Office Use of Betadine for Acute Adenoviral Conjunctivitis. November 2018. Presented at the American Academy of Optometry, San Antonio, Texas.
Hartwick ATE, et. al. Predictive Value of FDA-Approved Immunoassay for Adenoviral Conjunctivitis. May 2018. Presented at the 34th Annual Clinical Virology Symposium, West Palm Beach, Florida.
Whiteside, M, et. al. Reducing Adenoviral Patient Infected Days (RAPID) Study: Success in Masking Subjects and Clinicians From Identifying Treatment with Ophthalmic Povidone-Iodine 5%. April 2018. Presented at the Association for Research in Vision and Ophthalmology Annual Meeting, Honolulu, HI.
Migneco, M, et. el. Reducing Adenoviral Patient Infected Days (RAPID): Prevalence of PCR Confirmed Adenovirus Among Patients Presenting With Acute Conjunctivitis. April 2018. Presented at the Association for Research in Vision and Ophthalmology Annual Meeting, Honolulu, HI.
2017
Than T, et. al. Reducing Adenoviral Patient Infected Days (RAPID) Study: Association of Clinical Signs and Symptoms with qPCR Confirmed Adenoviral Conjunctivitis. October 2017. Presented at the American Academy of Optometry, Chicago, IL.
Shorter E, et. al. Reducing Adenoviral Patient Infected Days (RAPID) Study: Navigating Institutional Review Boards for a Multi-center Clinical Trial. October 2017. Presented at the American Academy of Optometry, Chicago, IL.
Shorter E, et. al. Reducing Adenoviral Patient Infected Days (RAPID) Study: Association of Clinical Signs and Symptoms with qPCR Confirmed Adenoviral Conjunctivitis. May 2017. Presented at the Association for Research in Vision and Ophthalmology Annual Meeting, Baltimore, Maryland. Abstract Number 4360-A0199.
2016
Migneco M, et. al. Reducing Adenoviral Patient Infected Days (RAPID) Planning Study: Agreement between Clinician and AdenoPlusTM in the Diagnosis of Adenoviral Conjunctivitis. May 2016. Presented at the Association for Research in Vision and Ophthalmology Annual Meeting, Seattle, WA. Abstract Number: 3503-A0106.
2015
Migneco M, et. al. Reducing Adenoviral Patient Infected Days (RAPID): Study Design and Baseline Characteristics. October 2015. Presented at the American Academy of Optometry, New Orleans, LA. Program Number 155226.